Novel Serum Biomarkers for Identifying Plaque Erosion in ACS and Predicting Prognosis (NBPE-ACS)

Xuebo Liu

Status: Active, not recruiting

Conditions: Acute Coronary Syndromes; Plaque Rupture

Treatments: Diagnostic Test: Blood is drawn to test for specific biomarkers

Study type: Observational

Funder types: Other

Identifiers

NCT06763835

TJH-2023-010

18411950300 (Other Grant/Funding Number)

ITJ(QN)2203 (Other Grant/Funding Number)

Details and patient eligibility

About

The goal of this observational study is to find novel serum biomarkers for the accurate diagnosis of plaque erosion (PE) from acute coronary syndrome (ACS) and help predicting the prognosis of PE. The main question it aims to answer is

• Whether novel serum biomarkers could facilitate the non-invasive diagnosis and prognosis prediction of PE ? Participants will be contacted at 1,2,5 year after the diagnosis of PE-ACS or other reasons of ACS.

Enrollment: 301 patients

Sex: All

Ages: 18 to 85 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

people presenting with an acute coronary syndrome (ACS)-either non-ST-segment elevation myocardial infarction (NSTE-ACS); or ST-segment elevation myocardial infarction (STE-ACS), and subsequently underwent emergent coronary angiography followed by percutaneous coronary intervention (PCI). Culprit leisions were tested using optical coheren tomograpgy and pathological diagnosis(PE OR PR) were validated by 2 independent experienced core lab members.

Exclusion criteria

• patients younger than 18 years or older than 85 years
• patients in cardiogenic shock
• prior coronary artery bypass grafting,
• patients with corornary stent thrombosis
• patients with left main coronary disease
• patients with congestive heart failure
• patients with life-threatening arrhythmia
• patients with thrombocytopenia patients with significant hepatic or renal impairment
• patients with septicemia, leukopenia, active inflammatory or malignant disease
• other factors compromising high-quality optical coherence tomography (OCT) imaging (e.g., severe vessel tortuosity or calcification, persistent no-reflow, lesions in distal segments, or an indeterminate culprit lesion)
• Individuals unable to provide informed consent were also excluded.

Trial design

301 participants in 2 patient groups

acute coronary syndrome casued by plaque erosion(PE-ACS)

Description:

acute coronary syndrome patients casued by plaque erosion as identified by invasive optical coherence tomography in catheter labs.(PE-ACS)

Treatment:

Diagnostic Test: Blood is drawn to test for specific biomarkers

acute coronary syndrome casued by plaque rupture(PR-ACS)

Description:

acute coronary syndrome patients casued by plaque rupture as identified by invasive optical coherence tomography in catheter labs.(PR-ACS)

Treatment:

Diagnostic Test: Blood is drawn to test for specific biomarkers